Lisata Therapeutics, Inc. LSTA
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Lisata Therapeutics, Inc. (LSTA) is a healthcare company listed in the US with a market value of about $13M. In the twelve months to September 30, 2026 it had revenue of $100000 and net income of -$17M, a net margin of -17159.0%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -70%.
About Lisata Therapeutics
Lisata Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $18M in 2014 to $170000 in 2025, a decline of about 34.5% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 68% over three years (dilution for shareholders). It spends 4676% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $100000 | $170000 | $1M | $0 | $0 | — | — | — | — | — | $35M |
| Net income | -$17M | -$17M | -$20M | -$21M | -$54M | -$27M | -$8M | -$19M | -$16M | $23M | -$33M |
| Free cash flow | -$22M | -$16M | -$19M | -$20M | -$21M | -$22M | -$9M | -$19M | -$20M | -$21M | -$25M |
| EPS (diluted) | $-1.88 | $-1.91 | $-2.40 | $-2.58 | $-10.47 | $-7.45 | $-7.95 | $-28.20 | $-25.05 | $38.40 | $-74.84 |
| Net margin | -17159.0% | -9756.5% | -1998.5% | — | — | — | — | — | — | — | -92.5% |
| ROIC | — | -115.9% | -72.5% | -47.7% | -82.1% | -29.6% | -45.7% | -92.2% | -45.0% | -31.8% | -280.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Lisata Therapeutics pay a dividend?
Not currently.
Is Lisata Therapeutics a good stock to buy?
We do not give buy or sell advice. Lisata Therapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.